Therapeutic Challenges in COVID-19

被引:2
作者
Maiti, Amit K. [1 ]
机构
[1] Mydnavar, Dept Genet & Genom, 28475 Greenfield Rd, Southfield, MI 48076 USA
关键词
SARS-CoV2; COVID-19; antibody; vaccine; mutation; immune response; IFIH1; interferon; SARS-COV-2; SPIKE-PROTEIN; RIG-I; RESVERATROL; EFFICACY; VIRUS; MDA5;
D O I
10.2174/1566524023666221222162641
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
SARS-CoV2 is a novel respiratory coronavirus and, understanding its molecular mechanism is a prerequisite to developing effective treatment for COVID-19. This RNA genome-carrying virus has a protein coat with spikes (S) that attaches to the ACE2 receptor at the cell surface of human cells. Several repurposed drugs are used to treat COVID-19 patients that are proven to be largely unsuccessful or have limited success in reducing mortalities. Several vaccines are in use to reduce the viral load to prevent developing symptoms. Major challenges to their efficacy include the inability of antibody molecules to enter cells but remain effective in the bloodstream to kill the virus. The efficacy of vaccines also depends on their neutralizing ability to constantly evolve new virus strains due to novel mutations and evolutionary survival dynamics. Taken together, SARS-CoV2 antibody vaccines may not be very effective and other approaches based on genetic, genomic, and protein interactome could be fruitful to identify therapeutic targets to reduce disease-related mortalities.
引用
收藏
页码:14 / 25
页数:12
相关论文
共 106 条
  • [1] A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness
    Ahmed, Sabeena
    Karim, Mohammad Mahbubul
    Ross, Allen G.
    Hossain, Mohammad Sharif
    Clemens, John D.
    Sumiya, Mariya Kibtiya
    Phru, Ching Swe
    Rahman, Mustafizur
    Zaman, Khalequ
    Somani, Jyoti
    Yasmin, Rubina
    Hasnat, Mohammad Abul
    Kabir, Ahmedul
    Aziz, Asma Binte
    Khan, Wasif Ali
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 103 : 214 - 216
  • [2] Cerebrovascular disease in COVID-19: Is there a higher risk of stroke?
    Altable, Marcos
    de la Serna, Juan Moises
    [J]. BRAIN BEHAVIOR & IMMUNITY-HEALTH, 2020, 6
  • [3] [Anonymous], 2021, CELL
  • [4] Immune mechanisms associated with sex-based differences in severe COVID-19 clinical outcomes
    Arnold, Cosby G.
    Libby, Anne
    Vest, Alexis
    Hopkinson, Andrew
    Monte, Andrew A.
    [J]. BIOLOGY OF SEX DIFFERENCES, 2022, 13 (01)
  • [5] Functions of the cytoplasmic RNA sensors RIG-I and MDA-5: Key regulators of innate immunity
    Barral, Paola M.
    Sarkar, Devanand
    Su, Zao-zhong
    Barber, Glen N.
    DeSalle, Rob
    Racaniello, Vincent R.
    Fisher, Paul B.
    [J]. PHARMACOLOGY & THERAPEUTICS, 2009, 124 (02) : 219 - 234
  • [6] Orchestrating the interferon antiviral response through the mitochondrial antiviral signaling (MAVS) adapter
    Belgnaoui, S. Mehdi
    Paz, Suzanne
    Hiscott, John
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2011, 23 (05) : 564 - 572
  • [7] Use of adenovirus type-5 vectored vaccines: a cautionary tale
    Buchbinder, Susan P.
    McElrath, M. Juliana
    Dieffenbach, Carl
    Corey, Lawrence
    [J]. LANCET, 2020, 396 (10260) : E68 - E69
  • [8] Russian SARS-CoV-2 vaccine
    Caddy, Sarah
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2020, 370
  • [9] Callaway Ewen, 2022, Nature, DOI 10.1038/d41586-022-02121-z
  • [10] Cappannoli Luigi, 2020, Chronic Dis Transl Med, V6, P246, DOI 10.1016/j.cdtm.2020.06.002